Combined chelation therapy with deferasirox and deferoxamine in thalassemia
A Lal, J Porter, N Sweeters, V Ng, P Evans… - Blood Cells, Molecules …, 2013 - Elsevier
Iron overload is the primary cause of mortality and morbidity in thalassemia major despite
advances in chelation therapy. We performed a pilot clinical trial to evaluate the safety and
efficacy of combined therapy with deferasirox (DFX, 20–30mg/kg daily) and deferoxamine
(DFO, 35–50mg/kg on 3–7days/week) in 22 patients with persistent iron overload or organ
damage. In the 18 subjects completing 12months of therapy, median liver iron concentration
decreased by 31% from 17.4 mg/g (range 3.9–38.2 mg/g) to 12.0 mg/g (range 0.96–26.7 …
advances in chelation therapy. We performed a pilot clinical trial to evaluate the safety and
efficacy of combined therapy with deferasirox (DFX, 20–30mg/kg daily) and deferoxamine
(DFO, 35–50mg/kg on 3–7days/week) in 22 patients with persistent iron overload or organ
damage. In the 18 subjects completing 12months of therapy, median liver iron concentration
decreased by 31% from 17.4 mg/g (range 3.9–38.2 mg/g) to 12.0 mg/g (range 0.96–26.7 …
